New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...

Research uncovers how inhibiting interactions between cyclin A and cyclin B and their key binding partners, E2F and MYT1, selectively kills E2F-high tumor cells Circle Pharma’s oral first-in-class ...

This highlight describes novel 2,6,9-trisubstituted purines as cyclin-dependent kinase 2 (CDK2) inhibitors. It details the novel 2,6,9-trisubstituted purine compounds, the pharmaceutical composition, ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#ASCO2025--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced ...

A "pocket" on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Two studies by researchers at the University of Konstanz investigated ...

A 'pocket' on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Cell division is key for life. Every organism -- from the smallest yeast ...

Researchers from Circle Pharma Inc. have presented preclinical data for CID-078, a novel orally bioavailable cyclin A/B Rxl macrocycle being developed for the treatment of patients with lung cancer.

Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...

The awe-inspiring process of cell division can turn a fertilized egg into a baby – or a cancerous cell into a malignant tumor. With so much at stake, nature keeps it tightly controlled in a process ...